BioSpace News Archive

Project to help each entity reach bold carbon-reduction goals U.S. Department of Energy to fund year-long study

Company innovates by incorporating key features of the new Apple Watch to improve and extend outcomes of PneumoBlast™ as a potential new COVID-19 therapy

Largest grant in Shepherd Center’s history will support the specialized rehabilitation hospital’s most significant expansion in 45 years

As a leading provider in teleradiology Rapid Radiology has received the golden seal of approval® presented by The Joint Commission Rapid Radiology has been awarded Re-accreditation from The Joint Commission

Pfizer and BioNTech Announce Publication of Results from Landmark Phase 3 Trial of BNT162b2 COVID-19 Vaccine Candidate in The New England Journal of Medicine Data from 43,448 participants, half of whom received BNT162b2 and half of whom received placebo, showed that the vaccine candidate was well tolerated and demonstrated 95% efficacy in preventing COVID-19 in those without prior infection 7 days or more after the second dose Vaccine efficacy o

Partnership Seeks to Lower Barriers to Evidence-Based Molecular Oncology Care by Extending Trapelo’s Decision Support Solutions Through Concert’s Network of Laboratories and Health Plans

Bayer and Tempus, leaders in precision medicine and artificial intelligence (AI), announced a new collaboration designed to provide broader access to genomic testing and tailored treatment approaches for the oncology community. The collaboration will include an initiative to help facilitate patient identification for precision oncology by providing testing, via the Tempus xT broad-panel genomic sequencing as

adMare today unveiled the six companies selected under its new acceleration program supported by the Quebec Government and the City of Montreal .

Genome Biologics UG, Frankfurt, Germany, today announced that they have entered into a research collaboration with AstraZeneca related to screening of proteins of the human secretome able to drive cardiac regeneration and recovery in Myocardial Infarction (MI), Heart Failure (HF) and Cardiotoxicity (CT).

Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced the presentation of blinded interim results from the Phase 2 RESCUE-ALS clinical trial investigating the effects of its lead clinical candidate, CNM-Au8, for the treatment of amyotrophic lateral sclerosis (ALS). CNM-Au8 is an aqueous suspension of clean-surfaced, faceted gold nanocrystals with catalytic activity that has been shown to enhance the metabolic ene